CD8A and cancer: Recent clinical trial data on patients with B cell non-Hodgkin lymphoma and chronic lymphocytic leukemia demonstrated the high anti-cancer activity of CD19-CAR-T cells generated from a composition of CD8+ and CD4+ T cell subsets that were separately expanded in vitro and infused at a ratio of 1:1 [33].